RFA-DA-22-003: Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $3.0 million in total. Applications closed on February 2, 2022.
From the official notice on Grants.gov, last changed June 23, 2021. Checked November 7, 2026.
- Total funding$3.0 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIDA
- Median yearly award$733,888
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-22-003 were run by National Institute on Drug Abuse (NIDA, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-22-003 in the NIH Guide.
Key dates
| Posted | June 23, 2021 |
|---|---|
| Deadline | February 2, 2022 |
| Archived by Grants.gov | March 10, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The National Institute on Drug Abuse [NIDA] seeks research proposals to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to an abused drug (including opioids, cocaine and stimulants, cannabinoids, and nicotine). The overall goal is to determine the contributions of antiretroviral [ARV] treatment regimens that are used to suppress viral load in the neurological and neurocognitive deficits that are associated with HIV-Associated Neurocognitive Disorders [HAND].
Funded under RFA-DA-22-003 so far
NIH funded 3 projects under RFA-DA-22-003 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $733,888.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Cellular and circuitry mechanisms of NRTI-induced pain pathogenesis in the context of opioids and HIV | State University New York Stony Brook | 2026 | $569,163 |
| cART, neuroHIV, cocaine abuse and the mPFC neuron/astrocyte dysfunction | Rush University Medical Center | 2026 | $759,014 |
| Role of GRIN2 in ART and SUD associated neurological deficits. | Meharry Medical College | 2026 | $726,919 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-22-003 still open?
No. It closed on February 2, 2022.
Who can apply for Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed)?
Closed February 2, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $3.0 million in total.
Who has been funded under RFA-DA-22-003?
NIH RePORTER lists 3 projects funded under RFA-DA-22-003 in fiscal 2022 to 2026, at 3 institutions. The most were at State University New York Stony Brook, Rush University Medical Center, Meharry Medical College.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)